Pharmaceutical Technology

APRIL 17, 2023

NKGen Biotech, a clinical-stage natural killer (NK) cell therapy firm, has signed a definitive agreement to combine its business operations with Graf Acquisition. NKGen Biotech will become a publicly traded company, while Graf will be rebranded as NKGen Biotech.

98

98

pharmaphorum

JUNE 4, 2021

The inaugural Prostate Cancer Drug Development Summit is the only industry-led meeting uniting large pharma, biotech and pioneering academics with the ambitious objective of accelerating the clinical development of safe and effective therapies to treat prostate cancer. Bringing theranostics to prostate cancer.

Drug Development 98

Drug Development 98

Pharma Leaders

JUNE 9, 2023

Biotech firm Promosome is the latest company to sue big pharma for infringing on its patent for messenger RNA (mRNA) technology during the rush to develop a COVID-19 vaccine, claiming in separate filings that Moderna and Pfizer reaped enormous profits using Promosome research. Promosome filed the suits Tuesday in the U.S.

Vaccines 40

Vaccines 40

pharmaphorum

NOVEMBER 2, 2021

The approach has become a hot topic in biopharma with a string of big ticket partnerships over the last couple of years, including a $2.4 Alongside Novartis, BioGeneration Ventures (BGV) has also come onboard as a new investor, with general partner Oskar Slotboom joining the biotech’s board.

98

98

Pharmaceutical Technology

MAY 22, 2023

The US Food and Drug Administration (FDA) has granted approval for Krystal Biotech’s Vyjuvek (beremagene geperpavec-svdt) to treat dystrophic epidermolysis bullosa (DEB) in patients aged six months and above. Vyjuvek is a non-invasive, topical, re-dosable gene therapy that delivers functional human COL7A1 gene copies to offer wound healing.

52

52

Pharmaceutical Technology

SEPTEMBER 9, 2022

US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). Topic sponsors are not involved in the creation of editorial content.

Compounding 98

Compounding 98

pharmaphorum

JANUARY 13, 2022

AstraZeneca has expanded its efforts to develop new therapies targeting transcription factors – proteins that regulate processes in the cell that have become a hot topic for drug discovery in cancer and other diseases. It’s not the big pharma’s first foray into the transcription factor area.

59

59

Express Pharma

AUGUST 29, 2023

The event is a key enabler in presenting ground-breaking innovations in pharma machinery, laboratory technologies and analytical instruments to user industries such as pharma, biotech, chemicals, F&B, etc. analytica Anacon India and India Lab Expo 2023 is jointly organised with IAIA.

Research Laboratories 96

Research Laboratories Packaging 96

pharmaphorum

AUGUST 28, 2020

Italian biotech Cassiopea has won US approval for Winlevi, a topical therapy it says is the first new approach to treating acne in nearly 40 years. The biotech isn’t revealing how much it intends to charge for the new medicine, saying it will do so closer to launch later this year.

Immunity 52

Immunity Immunization 52

pharmaphorum

AUGUST 17, 2021

Watch the video below to hear more on those topics and to find out more about PureTech’s interest in digital health, how that lines up alongside its focus on medicines, and some of the biotech company’s key partnerships. About the interviewee. Daphne Zohar is PureTech’s founder and CEO and a member of its board of directors.

Communication 111

Communication Immunity Immunization 111

pharmaphorum

OCTOBER 18, 2022

Oculis SA, a global biopharmaceutical company that develops treatments for saving sight and improving eye care with breakthrough innovations, is to combine with the European Biotech Acquisition Corp (EBAC), a special purpose acquisition company (SPAC) that has screened over 100 European biotechnology companies.

Diabetes 59

Diabetes 59

pharmaphorum

AUGUST 31, 2022

Futura Medical’s development of a topical treatment for erectile dysfunction (ED) is approaching the finish line in the US, as the UK biotech reports confirmatory phase 3 data ahead of an FDA filing later this month. ” The post Futura eyes FDA filing as topical ED drug passes phase 3 test appeared first on.

52

52

FDA Law Blog: Biosimilars

MARCH 6, 2024

The American Conference Institute (“ACI”) will be hosting a series of go-to forums on critical topics including novel therapeutics, cosmetics/personal care products and Paragraph IV disputes. HP&M is proud to have our professionals participating in these important events. On March 20-21, Counsel John W.M.

Pharmaceutical Manufacturing 59

Pharmaceutical Manufacturing Drug Development Pharmaceutical Companies Pharmaceutical Companies 59

Pharmaceutical Technology

APRIL 3, 2023

Sartorius , through its French listed sub-group Sartorius Stedim Biotech , has signed an agreement to acquire Polyplus for €2.4bn ($2.6bn). Topic sponsors are not involved in the creation of editorial content. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

98

98

pharmaphorum

OCTOBER 28, 2022

In June, NHSE and NICE published details on the Innovative Medicines Fund, which will help improve patient access to cutting-edge medicines, with a particular focus on rare diseases, and ensure global pharmaceutical and biotech organisations continue to prioritise the UK as a launch destination.

Biosimilars 122

Biosimilars 122

pharmaphorum

AUGUST 19, 2022

The German pharma acquired rights to the TRPV1 agonist also known as MTX-071 last year when it acquired Swiss biotech Mestex, and has started dosing patients in one of three planned phase 3 trials in osteoarthritis of the knee.

Diabetes 52

Diabetes Compounding 52

Pharmaceutical Technology

SEPTEMBER 21, 2022

Topic sponsors are not involved in the creation of editorial content. The post Rocket agrees to acquire biotech firm Renovacor appeared first on Pharmaceutical Technology. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

59

59

Drug Channels

JUNE 26, 2023

When you join Informa for this groundbreaking think-tank, you’ll find yourself in the company of experts from health systems, pharma/biotech manufacturers, integrated delivery networks, payers, and providers to hear novel case studies, regulatory updates and innovative models aimed at developing and maintaining collaborative, patient-centered partnerships. (..)

Biosimilars 62

Biosimilars 62

pharmaphorum

OCTOBER 9, 2018

Now more than ever before, Biotech is the engine for innovation in medicine, finding, creating and delivering ground-breaking treatments to patients. The journey from molecule discovery and development through valuation, funding, regulatory and commercialisation can be a long and complex road to travel though.

52

52

Drug Channels

SEPTEMBER 18, 2023

Benefit from key stakeholder interaction, dedicated breakouts, and detailed case studies on control enhancement and operational excellence to further strengthen your programming. Drug Channels subscribers: Save 10% off the current registration rate with promo code 21DC10*. Register today. Attorney , U.S.

66

66

Pharmaceutical Technology

FEBRUARY 16, 2023

The University of Texas MD Anderson Cancer Center has entered a strategic collaboration with biotech company Xilis for advancing new technology and expediting new cancer therapy development. Topic sponsors are not involved in the creation of editorial content.

Drug Development 96

Drug Development Communication 96

pharmaphorum

APRIL 7, 2021

Jan van de Winkel has overseen one of biotech’s big success stories since he took over Genmab’s CEO in 2010. He spoke to pharmaphorum’s news editor Richard Staines to outline his plans to create a European biotech powerhouse. . The last ten years has seen Denmark’s Genmab become one of biotech’s big success stories. billion). “It

Chemotherapy 91

Chemotherapy Hospitals Vaccines 91

Drug Channels

JUNE 14, 2021

Join us on August 10-12, 2021 as we delve into complex technical accounting hot topics, high-impact industry trends, deal-making, capital markets forecasts, global risks, technology innovations and more. Drug Channels readers will save 10% off the current rate when they use promo code 21DRCH10 and register prior to July 9th.*.

40

40

pharmaphorum

NOVEMBER 25, 2022

The pain products complement the German drugmaker’s current portfolio which includes a topical capsaicin product called Qutenza for post-shingles nerve pain and diabetic nerve pain affecting the feet, along with non-opioid analgesic resiniferatoxin which recently advanced into phase 3 testing in patients with osteoarthritis.

Diabetes 52

Diabetes 52

Pharmaceutical Technology

JUNE 8, 2023

The companies will offer a comprehensive suite of cell therapy services to biotech, pharmaceutical and government entities, and to hospitals. Topic sponsors are not involved in the creation of editorial content. The core objective of the collaboration is to make the therapies affordable and accessible to patients.

Vaccines 52

Vaccines Drug Development Immunity Immunization 52

pharmaphorum

AUGUST 27, 2020

Just two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could be a few months away from filing for approval of the drug. Now, Dermavant is only waiting for results of a long-term safety trial called PSOARING 3 before it moves ahead with a marketing application to the FDA.

52

52

Pharmaceutical Technology

MAY 17, 2023

At a lively panel at Financial Times US Pharma and Biotech Summit on May 16, panellists were at odds over whether the new legislation would improve treatment affordability or stifle pharma innovation. Insulin affordability has continued to prove a hot button topic as major pricing reforms are on the way.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

Pharmaceutical Technology

MAY 3, 2023

Janssen Biotech and the Cellular Biomedicine Group (CBMG) have entered a global collaboration and licence agreement for the development of next-generation chimeric antigen receptor (CAR) T-cell therapies to treat B-cell malignancies. Topic sponsors are not involved in the creation of editorial content.

59

59

Pharmaceutical Technology

DECEMBER 27, 2022

Drug pricing was a hot-button topic, and William Newton found that while e-commerce chains could cut insulin prices , any major change won’t happen overnight. You can sign up for newsletters to never miss the latest news on pharma and biotech, clinical trial strategy and operations , and medical devices. See you in 2023!

Vaccines 122

Vaccines Drug Development Drug Pricing 122

pharmaphorum

APRIL 5, 2022

“We designed the programme to touch on the topics that we believe everyone in the industry should at least be aware of. This will allow participants to revisit and review key topics around the heavy demands of their professional responsibilities. He is author of 100+ contributions on the topic of innovation in healthcare.

124

124

Pharmaceutical Technology

JANUARY 20, 2023

However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. On January 4, the company announced plans to acquire Japanese biotech OriCiro Genomics in an $85 million deal. In 2021, Moderna had a net income of $12.2

Vaccines 98

Vaccines Communication 98

pharmaphorum

FEBRUARY 7, 2019

Topics to be covered include: •Highlights of the 10-Year Plan and the second Sector Deal •Progress with the current Life Sciences Industrial Strategy, the Sector Deal and plans for 2019 •The NHS innovation uptake agenda •Maintaining UK attractiveness for inward global pharma and biotech investment

52

52

pharmaphorum

DECEMBER 14, 2020

The post 5th Microbiome Movement – Drug Development Summit Europe 2021 appeared first on.

Drug Development 52

Drug Development 52

pharmaphorum

NOVEMBER 1, 2022

Further topics to be examined comprise of novel RNA modalities encompassing self-amplifying RNA, saRNA, circular RNA, lnc RNA and many more. We will also explore the latest trends in novel RNA therapies, including developments in AI modelling and small molecule modulation of RNA.

Clinical Pharmacology 52

Clinical Pharmacology 52

pharmaphorum

JULY 8, 2022

Real-world evidence is a hot topic across the pharmaceutical industry,” says Naomi Fried, PhD, PharmStars’ founder and CEO. PharmStars is also currently accepting a limited number of additional pharma and biotech members for this cohort and for 2023. Information on membership can be found at www.PharmStars.com. PharmStars.

Drug Development 52

Drug Development 52

Drug Channels

SEPTEMBER 20, 2021

Informa Connect's Pharma/Biotech GTN Summit. Hybrid Event In-Person: November 17-19, 2021 in Philadelphia Virtual: November 22-23, 2021 www.informaconnect.com/gtn. Join the life sciences community this fall at Informa Connect’s GTN Summit , now in the 11th year. Visit www.informaconnect.com/gtn for further details and to register.

Drug Pricing 65

Drug Pricing 65

pharmaphorum

JANUARY 24, 2022

Key Reasons to Attend: Discover the main topics of research within industry, with talks on decision making, target selection and closing the loop. CEOs, Presidents, Vice Presidents and Global Heads, Executive Directors, Vice President & Global head, Principal Scientists, Heads of Business Development, Directors of Pharma/Biotech firms.

Compounding 52

Compounding Drug Development 52